Affiliation:
1. V.I. Vernadsky Crimean Federal University
Abstract
256 patients with type 2 diabetes and arterial hypertension (AH) were examined. The blood aldosterone level was determined in all patients, 24-hour blood pressure monitoring (BPM) and echodopplercardiography were performed, and the parameters of arterial vascular stiffness were studied. Results. In patients with type 2 diabetes and hypertension, the level of aldosterone in the blood ranged from 25 to 186 pg / ml, which corresponded to the reference norm. Patients with a level of aldosterone less than 25 percentile accounted for 15% of the examined - group I; Group II - patients with middle aldosterone levels (25-75 percentiles) - 46%; with a level more than 75 percentile - 39%, were included in group III. In the studied groups, office blood pressure (BP) did not depend on the level of aldosterone, however, in patients with both aldosterone levels above the 75th percentile and below the 25th percentile, an increase in the average daily pulse BP and an insufficient degree of nighttime BP reduction were revealed during BPM. Similarly, in groups I and III, there was a statistically significant increase in arterial stiffness indicators, compared with individuals with an average level of aldosterone. Disorders of diastolic function and LV hypertrophy were also more pronounced in groups of patients with aldosterone levels less than the 25th and more than 75th percentile. Conclusion. In patients with type 2 diabetes, the level of blood aldosterone less than the 25th and more than 75th percentile within the reference norm is associated with a greater severity of myocardial and arterial vessel remodeling processes.
Subject
Process Chemistry and Technology,Economic Geology,Fuel Technology
Reference17 articles.
1. Mirabito Colafella K. M, Danser AHJ. Recent advances in angiotensin research. Hypertension. 2017;69:994–999. doi:0.1161/ HYPERTENSIONAHA.117.08931., Mirabito Colafella K. M, Danser AHJ. Recent advances in angiotensin research. Hypertension. 2017;69:994–999. doi:0.1161/ HYPERTENSIONAHA.117.08931.
2. Neves M. F., Cunha A. R., Cunha M. R., Gismondi R. A., Oigman W. The Role of Renin– Angiotensin–Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. High Blood Pressure & Cardiovascular Prevention. 2018;25:137–145. doi:10.1007/s40292-018-0252-5., Neves M. F., Cunha A. R., Cunha M. R., Gismondi R. A., Oigman W. The Role of Renin– Angiotensin–Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. High Blood Pressure & Cardiovascular Prevention. 2018;25:137–145. doi:10.1007/s40292-018-0252-5.
3. Aroor A. R., Demarco V. G., Jia G., Sun Z., Nistala R., Meininger G. A. The role of tissue renin- angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Frontiers in endocrinology. 2013;4:161. doi: 10.3389/ fendo.2013.00161., Aroor A. R., Demarco V. G., Jia G., Sun Z., Nistala R., Meininger G. A. The role of tissue renin- angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Frontiers in endocrinology. 2013;4:161. doi: 10.3389/ fendo.2013.00161.
4. Lother A., Hein L. Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease. Hypertension. 2016;68:6–10. doi: 10.1161/ HYPERTENSIONAHA.116.07418., Lother A., Hein L. Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease. Hypertension. 2016;68:6–10. doi: 10.1161/ HYPERTENSIONAHA.116.07418.
5. Briet M., Schiffrin E. L. Vascular actions of aldosterone. Journal of vascular research. 2013;50:89– 99. doi: 10.1159/000345243., Briet M., Schiffrin E. L. Vascular actions of aldosterone. Journal of vascular research. 2013;50:89– 99. doi: 10.1159/000345243.